MET and melanoma: Our prior studies had shown STAT3 activation was an evolutionary survival response in [pazopanib + AR42] treated melanoma tumors; this, together with our present findings, argues that a c-MET – STAT3/STAT5 signaling pathway may be a key evolutionary survival signaling module that is selected for in melanoma after [pazopanib + AR42] exposure [1].